Latest therapies for bipolar disorder

References

• Bauer MS, Mitchner L. What is a “mood stabilizer”? An evidence-based response. Am J Psychiatry 2004; 161(1): 3–18
   PubMed Web of Science ®Google Scholar
• Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004; 12(1): 14–41
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Harrow M, Sands JR. Lithium therapy in the longitudinal course of bipolar disorder. Psychiatr Ann 1996; 26(10): 651–8
   Google Scholar
• Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161(2): 217–22
   PubMed Web of Science ®Google Scholar
• Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48(1): 62–8
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271(12): 918–24 [Erratum, JAMA 1994; 271(23): 1830]
   PubMed Web of Science ®Google Scholar
• Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30(2): 229–33
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Markovitz PJ, Rimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12(1 Suppl): 53–6S
   Google Scholar
• Shelton MD III, Rapport DJ, Youngstrom EA, et al. Is rapid cycling a predictor of nonresponse to lithium? Poster NR759. Presented at the 157th American Psychiatric Association Annual Meeting, May 1–6, 2004, New York
   Google Scholar
• Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156(8): 1264–6
   PubMedGoogle Scholar
• Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54(1): 37–42
   PubMedGoogle Scholar
• Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62(1): 37–45
   PubMed Web of Science ®Google Scholar
• Weisler RH, Kalali AH, Ketter TA, for the SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65(4): 478–84
   PubMed Web of Science ®Google Scholar
• Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 2003; 23(2): 182–92
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65(3): 432–41
   PubMed Web of Science ®Google Scholar
• McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2): 255–61 [Erratum, Am J Psychiatry 2003; 160(3): 612]
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361 (9370): 1677–85
   PubMed Web of Science ®Google Scholar
• Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 2002; 22(6): 584–91
   PubMed Web of Science ®Google Scholar
• Thorazine package insert. Research Triangle Park, NC: GlaxoSmithKline, 2001. Available at: http://www.fda.gov/cder/foi/label/2001/11120s86lbl.pdf. Accessed Jan 5, 2005
   Google Scholar
• Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004; 161(1): 169–71
   PubMedGoogle Scholar
• Citrome L, Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004; 116(4): 49–63
   PubMed Web of Science ®Google Scholar
• Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Bare) 2004; 40(5): 445–64
   PubMedGoogle Scholar
• Calabrese JR, Macfadden M, McCoy R, et al. Double-blind, placebo- controlled study of quetiapine in bipolar depression. Presented at the 157th Annual Meeting of the American Psychiatric Association, May 1–6, 2004, New York
   Google Scholar
• Citrome L, Goldberg JF, Stahl SM. Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry (in press)
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4 Suppl): 1–50
   Web of Science ®Google Scholar
• Tohen M, Mameros A, Bowden C, et al. Olanzapine versus lithium in relapse prevention in bipolar disorder. Poster NR509. Presented at the 156th American Psychiatric Association Annual Meeting, May 17–22, 2003, San Francisco
   Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a doubleblind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159(7): 1146–54
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6(3): 213–23
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser versus mood stabiliser alone. Br J Psychiatry 2004; 184(April): 337–45
   PubMed Web of Science ®Google Scholar